Travere Therapeutics Inc. (NASDAQ:TVTX) went down by -1.88% from its latest closing price compared to the recent 1-year high of $33.09. The company’s stock price has collected 1.88% of gains in the last five trading sessions. Press Release reported on 06/05/21 that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. – TVTX
Is It Worth Investing in Travere Therapeutics Inc. (NASDAQ :TVTX) Right Now?
Plus, the 36-month beta value for TVTX is at 0.69. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for Travere Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $31.13. Today, the average trading volume of TVTX was 632.54K shares.
TVTX’s Market Performance
TVTX stocks went up by 1.88% for the week, with a monthly drop of -26.37% and a quarterly performance of -49.11%, while its annual performance rate touched -3.66%. The volatility ratio for the week stands at 4.24% while the volatility levels for the past 30 days are set at 4.99% for Travere Therapeutics Inc.. The simple moving average for the period of the last 20 days is -11.55% for TVTX stocks with a simple moving average of -37.92% for the last 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Wedbush repeating the rating for TVTX by listing it as a “Neutral.” The predicted price for TVTX in the upcoming period, according to Wedbush is $19 based on the research report published on May 26th of the current year 2021.
TVTX Trading at -31.43% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.88% of loss for the given period.
Volatility was left at 4.99%, however, over the last 30 days, the volatility rate increased by 4.24%, as shares sank -24.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.97% lower at present.
During the last 5 trading sessions, TVTX rose by +1.88%, which changed the moving average for the period of 200-days by -23.24% in comparison to the 20-day moving average, which settled at $16.27. In addition, Travere Therapeutics Inc. saw -46.43% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TVTX starting from Dube Eric M, who sale 4,780 shares at the price of $14.35 back on Jun 02. After this action, Dube Eric M now owns 147,251 shares of Travere Therapeutics Inc., valued at $68,593 using the latest closing price.
Dube Eric M, the Chief Executive Officer of Travere Therapeutics Inc., sale 4,782 shares at $14.89 during a trade that took place back on Jun 01, which means that Dube Eric M is holding 152,031 shares at $71,204 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -38.01 for the present operating margin
- +85.60 for the gross margin
The net margin for Travere Therapeutics Inc. stands at -85.43. The total capital return value is set at -16.91, while invested capital returns managed to touch -38.15. Equity return is now at value -75.10, with -32.70 for asset returns.
Based on Travere Therapeutics Inc. (TVTX), the company’s capital structure generated 115.54 points at debt to equity in total, while total debt to capital is 53.60. Total debt to assets is 40.17, with long-term debt to equity ratio resting at 115.37. Finally, the long-term debt to capital ratio is 53.53.
When we switch over and look at the enterprise to sales, we see a ratio of 5.94, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 7.76 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.43.